The National Human Genome Research Institute's Division of Intramural Research will present the 14th Jeffrey M. Trent Lecture in Cancer Research on March 15, 2018, 12:00 - 1:00 p.m., at the Lipsett Amphitheater, Building 10 (Clinical Center), on the National Institutes of Health (NIH) Bethesda campus. Joan Brugge, Ph.D., co-director, Ludwig Center at Harvard Medical School, will deliver the lecture Role of the TRPA1 Ca2+-permeable Channel in Oxidative Stress Defenses in Cancer.
A pioneer in the field of cancer biology, Dr. Brugge has devoted her career to proving how disturbances in normal cellular processes give rise to cancer. From her early isolation of the protein encoded by the src transforming gene of Rous sarcoma virus, to the evolving understanding of the cellular processes and pathways responsible for the initiation and progression of epithelial tumors, to the use of three-dimensional culture conditions to reveal significant changes in the organization of normal tissue associated with cancer, hers has been a lifelong journey to discover how cells regulate the mechanisms that contribute to human carcinogenesis.
Dr. Brugge's laboratory team is currently studying multiple aspects of tumor cell biology in order to identify vulnerabilities of tumor cells that can be targeted for therapeutic intervention and to develop startegies to overcome mechanisms that drive therapy resistance. In addition, her group is investigating the nature of cooperative interactions between tumor cell populations and mutual dependencies among tumor cell variants and how these affect tumor expansion or metastasis. Dr. Brugge has recently assumed leadership of the Ludwig Center at Harvard, a collaborative initiative that is focused on developing new strategies to overcome cancer therapy resistance.
Dr. Brugge takes pride in the accomplishments of her group at Harvard and especially enjoys the mentoring process. In an interview for AACR's Cancer Discovery, she stated that she encourages her fellows to be independent thinkers and empowers them to follow their ideas wherever they may lead them.
Jeffrey M. Trent, Ph.D., F.A.C.M.G, was the National Human Genome Research Institute's (NHGRI) founding scientific director, serving in this role for more than nine years. His leadership and vision were instrumental in establishing NHGRI's Division of Intramural Research as one of the premier research programs in the world devoted to genetics and genomics. In recognition of his significant contributions to the research environment at the National Institutes of Health (NIH), NHGRI established the annual Jeffrey M. Trent Lecture in Cancer Research in 2003. This lecture is given by a prominent cancer researcher who brings the kind of energy, creativity and enthusiasm to cancer research that Dr. Trent has exemplified throughout his career.
Dr. Trent received his undergraduate degree from Indiana University, Bloomington, and his M.S. and Ph.D. degrees in genetics from the University of Arizona, Tucson. Prior to joining NHGRI, he was the Emanuel N. Maisel Professor of Oncology and Professor of Radiation Oncology and Human Genetics at the University of Michigan, Ann Arbor. He also served as director of the Division of Cancer Biology, and director of basic sciences at the University of Michigan Comprehensive Cancer Center. In 1993, Dr. Trent came to NIH with Dr. Francis Collins to establish and direct its newly formed Division of Intramural Research. Following his departure from NHGRI, Dr. Trent became the founding president and research director of the Translational Genomics Research Institute (TGen) in Phoenix.
Dr. Trent's research has provided important insights into the genetic basis of cancer. He is the author of more than 350 manuscripts in the scientific literature, numerous book chapters, invited reviews, and has given hundreds of invited lectures. He has received numerous honors and awards, and has sat on the editorial boards of a dozen scientific publications. He specializes in developing and integrating novel "omic" technologies, in support of clinical decision support in oncology patients.
Dr. Trent continues to lead studies of the genetic basis of various complex diseases in humans, as well as leading TGen's canine hereditary cancer program.
For additional information:
Last Updated: March 14, 2018